Cargando…

Using menopause status and 21-gene expression assay to inform chemotherapy benefit in node-positive breast cancer

Detalles Bibliográficos
Autores principales:	Davey, Matthew G., Kerin, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338149/ https://www.ncbi.nlm.nih.gov/pubmed/35810248 http://dx.doi.org/10.1007/s10549-022-06671-8

Ejemplares similares

Relevance of the 21-gene expression assay in male breast cancer: A systematic review and meta-analysis
por: Davey, Matthew G., et al.
Publicado: (2022)

Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score
por: Jacobson, Anne
Publicado: (2022)

Evaluating the Clinical Utility of Routine Sentinel Lymph Node Biopsy and the Value of Adjuvant Chemotherapy in Elderly Patients Diagnosed With Oestrogen Receptor Positive, Clinically Node Negative Breast Cancer
por: Davey, Matthew G, et al.
Publicado: (2021)

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
por: Geyer, Charles E., et al.
Publicado: (2018)

Value of the 21-gene expression assay in predicting locoregional recurrence rates in estrogen receptor-positive breast cancer: a systematic review and network meta-analysis
por: Davey, Matthew G., et al.
Publicado: (2022)

Neoadjuvant Therapy Should Be the Standard of Care for Every Node Positive Breast Cancer Patient
por: Hamdy, Omar
Publicado: (2018)

Lymph node density as a surrogate marker for positive lymph nodes
por: Van Gorp, T, et al.
Publicado: (2011)

Potential Benefits of Neoadjuvant Chemotherapy in Clinically Node-Positive Luminal Subtype(−) Breast Cancer
por: Kim, Hyung Suk, et al.
Publicado: (2019)

Reply: Lymph node density as a surrogate marker for positive lymph nodes
por: Polterauer, S, et al.
Publicado: (2011)

Downregulation of miRNA-21 and cancer stem cells after chemotherapy results in better outcome in breast cancer patients
por: Dwivedi, Shailendra, et al.
Publicado: (2022)

p21 is necessary for the beneficial effects of fasting during chemotherapy
por: Plaza, Adrián, et al.
Publicado: (2022)

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
por: Eiermann, W., et al.
Publicado: (2013)

Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
por: Bertucci, François, et al.
Publicado: (2023)

Menopausal spectrum of urban Indian women
por: Malla, Veena Ganju, et al.
Publicado: (2014)

Social issues in post menopausal women
por: Bhutani, Sukriti, et al.
Publicado: (2013)

MicroRNA Expression Profiles and Breast Cancer Chemotherapy
por: Davey, Matthew G., et al.
Publicado: (2021)

The Role of the 21-Gene Recurrence Score(®) Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience
por: Yordanova, Mariya, et al.
Publicado: (2022)

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2015)

21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes
por: Tong, Yiwei, et al.
Publicado: (2019)

Techniques for sentinel node detection in breast cancer
por: Lee, Joseph C., et al.
Publicado: (2020)

Menopause and the Loss of Skeletal Muscle Mass in Women
por: KO, Jupil, et al.
Publicado: (2021)

Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2− node positive breast cancer—A National Cancer Database study
por: Peethambaram, Prema P., et al.
Publicado: (2017)

The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients
por: Stemmer, Salomon M., et al.
Publicado: (2013)

Evaluation of menopausal status among breast cancer patients with chemotherapy-induced amenorrhea
por: Zhang, Bailin, et al.
Publicado: (2018)

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer
por: Kümmel, S, et al.
Publicado: (2006)

Benefits of a national network of drug information centres: RELIS
por: Schjøtt, Jan
Publicado: (2016)

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2016)

No benefit of chemotherapy in Osimertinib-treated postoperative non-small cell lung cancer patients
por: Li, Feng, et al.
Publicado: (2021)

The Annual Conference of the British Menopause Society – June 2010
por: Shah, Duru
Publicado: (2010)

Commentary on following of Menopausal Guidelines by practitioners in Indian setting
por: Borker, Sagar, et al.
Publicado: (2014)

Effects of Menopause on Physical Activity and Dopamine Signaling in Women
por: Kim, Dong-Il, et al.
Publicado: (2022)

Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy
por: Pettengell, R., et al.
Publicado: (2008)

Adjuvant Trastuzumab Is Required in Human Epidermal Growth Factor Receptor 2-Positive Node-Negative Breast Cancer Patients Regardless of Tumour Size
por: Bender, Laura, et al.
Publicado: (2020)

m(6)A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer
por: Zhang, Zhihui, et al.
Publicado: (2021)

Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: A systematic review and meta-analysis
por: Davey, M.G., et al.
Publicado: (2021)

Internet chemotherapy information is of good quality: assessment with the DISCERN tool
por: Som, R, et al.
Publicado: (2012)

Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
por: Poorvu, Philip D., et al.
Publicado: (2020)

Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
por: Kim, Hee Jeong, et al.
Publicado: (2020)

Evaluating the Fragility of Long-Term Outcomes for Neoadjuvant versus Adjuvant Chemotherapy Prescription in Early Breast Cancer: Pooled Data from 10 Randomised Clinical Trials
por: Davey, Matthew G, et al.
Publicado: (2022)

Prediction of neoadjuvant chemotherapy response in breast cancer
por: Myllys, Maiju
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_umgg8g0i0jupg43vp7flckitve